 |
Top 18 Hepatitis treatment startups
Oct 10, 2024 | By Jason Kwon | 18 |
These startups develop new diagnostics and treatment technologies for Hepatitis, like gene editing therapies, direct-acting antiviral drugs, non-invasive liver fibrosis testing, point-of-care testing devices, HCV genotyping assays, CRISPR-based antiviral treatments
1
Country: USA | Funding: $498.5M
Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global nonalcoholic steatohepatitis (NASH) burden.
Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global nonalcoholic steatohepatitis (NASH) burden.
2
Country: USA | Funding: $908.6M
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
3
Country: USA | Funding: $899.9M
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
4
Country: USA | Funding: $765M
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
5
Country: USA | Funding: $433.5M
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
6
Country: USA | Funding: $400.6M
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
7
Country: USA | Funding: $265.2M
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
8
Country: USA | Funding: $200.4M
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
9
Country: USA | Funding: $167M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
10
Country: Netherlands | Funding: $149.4M
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
